Deepening of Lid Sulcus from Topical Bimatoprost Ther

Optometry and Vision Science
81, 574-577
DOI: 10.1097/01.opx.0000141791.16683.4a

Citation Report

#	Article	IF	Citations
1	Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety, 2005, 14, i-xii.	1.9	0
2	Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy. Optometry - Journal of the American Optometric Association, 2006, 77, 177-179.	0.6	8
3	The side effects of the prostaglandin analogues. Expert Opinion on Drug Safety, 2007, 6, 45-52.	2.4	141
4	Periorbital Changes Associated With Topical Bimatoprost. Ophthalmic Plastic and Reconstructive Surgery, 2008, 24, 302-307.	0.8	115
5	Bilateral Deepening of Upper Lid Sulcus From Topical Bimatoprost Therapy. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 471-472.	1.4	54
6	Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Japanese Journal of Ophthalmology, 2009, 53, 18-23.	1.9	22
7	Deepening of eyelid superior sulcus during topical travoprost treatment. Japanese Journal of Ophthalmology, 2009, 53, 176-179.	1.9	57
8	Bimatoprost in the treatment of eyelash hypotrichosis. Clinical Ophthalmology, 2010, 4, 349.	1.8	62
9	Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature. Cutaneous and Ocular Toxicology, 2010, 29, 212-216.	1.3	34
10	Periorbital Fat Atrophy â€" An Unfamiliar Side Effect of Prostaglandin Analogues. Orbit, 2010, 29, 357-359.	0.8	80
11	Latanoprost Therapy After Sunken Eyes Caused by Travoprost or Bimatoprost. Optometry and Vision Science, 2011, 88, 1140-1144.	1.2	34
12	Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Japanese Journal of Ophthalmology, 2011, 55, 22-27.	1.9	103
13	Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Japanese Journal of Ophthalmology, 2011, 55, 600-604.	1.9	63
14	The biology, pathology and therapeutic use of prostaglandins in the eye. Clinical Lipidology, 2011, 6, 577-591.	0.4	9
15	Topical Bimatoprost 0.03% and Iatrogenic Eyelid and Orbital Lipodystrophy. Aesthetic Surgery Journal, 2012, 32, 822-824.	1.6	20
16	In Vitro Study of Antiadipogenic Profile of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in Human Orbital Preadiopocytes. Journal of Ocular Pharmacology and Therapeutics, 2012, 28, 146-152.	1.4	48
17	A review of the use of latanoprost for glaucoma since its launch. Expert Opinion on Pharmacotherapy, 2012, 13, 723-745.	1.8	67
18	Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension. Clinical Ophthalmology, 2012, 6, 111.	1.8	12

#	Article	IF	Citations
19	Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma. Clinical Ophthalmology, 2012, 7, 7.	1.8	8
20	Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 123-129.	1.9	13
21	Anandamide-derived Prostamide F2Î± Negatively Regulates Adipogenesis. Journal of Biological Chemistry, 2013, 288, 23307-23321.	3.4	43
22	Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases. Japanese Journal of Ophthalmology, 2013, 57, 172-178.	1.9	25
23	Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Japanese Journal of Ophthalmology, 2013, 57, 179-184.	1.9	40
24	Acute Effects of Glaucoma Medications and Benzalkonium Chloride on Pre-adipocyte Proliferation and Adipocyte CytotoxicityIn Vitro. Current Eye Research, 2013, 38, 70-74.	1.5	14
25	The coming age of enophthalmos. Current Opinion in Ophthalmology, 2013, 24, 500-505.	2.9	9
26	Deepening of the Upper Eyelid Sulcus Caused by 5 Types of Prostaglandin Analogs. Journal of Glaucoma, 2013, 22, 626-631.	1.6	71
27	Minimally Invasive Approaches to Orbital Volume Augmentation. International Ophthalmology Clinics, 2013, 53, 67-86.	0.7	1
28	Effects of Prostaglandin F2Î± on Adipocyte Biology Relevant to Graves' Orbitopathy. Thyroid, 2013, 23, 1600-1608.	4.5	24
29	Recent Progress in Prostaglandin F2Î±Ethanolamide (Prostamide F2Î±) Research and Therapeutics. Pharmacological Reviews, 2013, 65, 1135-1147.	16.0	42
30	Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patients. Clinical Ophthalmology, 2013, 7, 1441.	1.8	13
31	A Cross-Sectional Survey of the Association between Bilateral Topical Prostaglandin Analogue Use and Ocular Adnexal Features. PLoS ONE, 2013, 8, e61638.	2.5	73
32	Managing adverse effects of glaucoma medications. Clinical Ophthalmology, 2014, 8, 903.	1.8	103
33	Prostaglandin-associated periorbitopathy in latanoprost users. Clinical Ophthalmology, 2014, 9, 51.	1.8	31
34	Periorbital muscle atrophy associated with topical bimatoprost therapy. Clinical Ophthalmology, 2014, 8, 311.	1.8	12
35	Topical Prostaglandin Analogue Drugs Inhibit Adipocyte Differentiation. Korean Journal of Ophthalmology: KJO, 2014, 28, 257.	1.1	5
36	Activation of the Prostanoid FP Receptor Inhibits Adipogenesis Leading to Deepening of the Upper Eyelid Sulcus in Prostaglandin-Associated Periorbitopathy. , 2014, 55, 1269.		68

#	Article	IF	Citations
37	Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clinical and Experimental Ophthalmology, 2014, 42, 126-131.	2.6	88
38	Effectiveness of the ICare rebound tonometer in patients with overestimated intraocular pressure due to tight orbit syndrome. Japanese Journal of Ophthalmology, 2014, 58, 496-502.	1.9	12
39	Bimatoprost: a unique compound that in its nonhydrolyzed form is a prostamide and hydrolyzed form has prostaglandin receptor activity, for glaucoma and cosmetic indications. Expert Review of Ophthalmology, 2014, 9, 159-173.	0.6	1
40	Incidence of Deepening of the Upper Eyelid Sulcus After Topical Use of Travoprost Ophthalmic Solution in Japanese. Journal of Glaucoma, 2014, 23, 160-163.	1.6	22
41	Hirsutism following the use of bimatoprost eyedrops for glaucoma. Journal of Pharmacology and Pharmacotherapeutics, 2014, 5, 208-210.	0.4	2
42	Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Japanese Journal of Ophthalmology, 2014, 58, 212-217.	1.9	38
43	Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution. Eye, 2014, 28, 1446-1451.	2.1	29
44	A general analytical platform and strategy in search for illegal drugs. Journal of Pharmaceutical and Biomedical Analysis, 2014, 100, 215-229.	2.8	42
45	Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol. Drug Design, Development and Therapy, 2015, 9, 2617.	4.3	4
46	The Pharmacology of Prostaglandin F2Î± Ethanolamide and Bimatoprost Reveals a Unique Feedback Mechanism on Endocannabinoid Actions. , 2015, , 85-99.		0
47	Oxidative Metabolites of Endocannabinoids Formed by Cyclooxygenase-2. , 2015, , 49-65.		0
48	Observations on Prostaglandin Orbitopathy. Ophthalmic Plastic and Reconstructive Surgery, 2016, 32, 102-105.	0.8	21
49	Prostaglandin Eyedrops Are Associated With Decreased Thicknesses of Eyelid Dermis and Orbicularis Oculi Muscle: Ultrasonographic Findings. Ophthalmic Plastic and Reconstructive Surgery, 2016, 32, 337-341.	0.8	7
50	A Vector Force Model of Upper Eyelid Position in the Setting of a Trabeculectomy Bleb. Ophthalmic Plastic and Reconstructive Surgery, 2016, 32, 127-132.	0.8	3
51	PeriorbitopatÃa asociada a prostaglandinas. Archivos De La Sociedad Espanola De Oftalmologia, 2016, 91, 207-208.	0.2	0
52	Oculoplastic considerations in patients withÂglaucoma. Survey of Ophthalmology, 2016, 61, 718-725.	4.0	18
53	The exit strategy: Pharmacological modulation of extracellular matrix production and deposition for better aqueous humor drainage. European Journal of Pharmacology, 2016, 787, 32-42.	3.5	24
54	Thyroid eye disease- an update. Expert Review of Ophthalmology, 2016, 11, 273-284.	0.6	14

#	Article	IF	Citations
55	Medical Treatment: First-Line Agents, Monotherapy, and Combination Therapy. , 2016, , 227-242.		0
56	Prostaglandin associated periorbitopathy. Archivos De La Sociedad Espanola De Oftalmologia, 2016, 91, 207-208.	0.2	0
57	Clicking Eyelids: A New Finding of Prostaglandin-Associated Periorbitopathy. Optometry and Vision Science, 2016, 93, 779-781.	1.2	7
58	Retrospective Evaluation of Topical Bimatoprost and Iris Pigmentation Change. Dermatologic Surgery, 2017, 43, 1431-1433.	0.8	4
59	Structural and Histologic Eyelid Changes Associated with 6 Months of Topical Bimatoprost in the Rabbit. Journal of Glaucoma, 2017, 26, 253-257.	1.6	4
60	Changes in Sunken Eyes Combined with Blepharoptosis after Levator Resection. Plastic and Reconstructive Surgery - Global Open, 2017, 5, e1616.	0.6	7
61	Factors Related to Prostaglandin-Associated Periorbitopathy in Glaucoma Patients. Asia-Pacific Journal of Ophthalmology, 2017, 6, 238-242.	2.5	11
62	Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS ONE, 2017, 12, e0181550.	2.5	28
63	Periorbital changes associated with prostaglandin analogs in Korean patients. BMC Ophthalmology, 2017, 17, 126.	1.4	16
64	Unilateral orbital fat change. BMJ Case Reports, 2018, 2018, bcr-2017-223525.	0.5	1
65	Effect of prostaglandin analogs on matrix metalloproteinases and tissue inhibitor of metalloproteinases in eyelid muscle specimens. Clinical Ophthalmology, 2018, Volume 12, 2039-2046.	1.8	9
66	Factors associated with fluctuations in repeated measurements of intraocular pressure using the Goldmann applanation tonometer in Japanese patients with primary open-angle glaucoma. Clinical Ophthalmology, 2018, Volume 12, 1473-1478.	1.8	8
67	In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma. In Vivo, 2018, 32, 211-220.	1.3	23
68	The Degree of Posttraumatic Enophthalmos Detectable by Lay Observers. Facial Plastic Surgery, 2019, 35, 306-310.	0.9	0
69	Prostaglandin F2-Alpha Eye Drops (Bimatoprost) in Graves' Orbitopathy: A Randomized Controlled Double-Masked Crossover Trial (BIMA Trial). Thyroid, 2019, 29, 563-572.	4.5	11
70	Shortening of Interpupillary Distance after Instillation of Topical Prostaglandin Analog Eye Drops. American Journal of Ophthalmology, 2019, 206, 11-16.	3.3	5
71	Structural features of eyelid connective tissue in patients with primary open-angle glaucoma. International Ophthalmology, 2019, 39, 2005-2014.	1.4	0
72	Effectiveness of Blepharoptosis Surgery in Patients With Deepening of the Upper Eyelid Sulcus. Journal of Craniofacial Surgery, 2020, 31, 1284-1286.	0.7	1

#	Article	IF	Citations
73	Prostaglandin-Associated Periorbitopathy in Children and Young Adults with Glaucoma. Ophthalmology Glaucoma, 2020, 3, 288-294.	1.9	3
74	Orbital Fat Volume After Treatment with Topical Prostaglandin Agonists. , 2020, 61, 46.		1
75	Prostaglandin F2Î± Agonists Negatively Modulate the Size of 3D Organoids from Primary Human Orbital Fibroblasts. , 2020, 61, 13.		46
76	Prostaglandin analogues: A double-edged sword in orbital glaucoma disease management. European Journal of Ophthalmology, 2020, 31, 112067212090529.	1.3	2
77	Drugs Used in Ophthalmology. , 2021, , 413-499.		0
78	Corneal topographic changes after blepharoptosis surgery in patients with deepening of the upper eyelid sulcus. Japanese Journal of Ophthalmology, 2021, 65, 282-287.	1.9	3
79	Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products. Dermatologic Surgery, 2021, 47, 658-665.	0.8	7
80	ROCK inhibitors enhance the production of large lipid-enriched 3D organoids of 3T3-L1 cells. Scientific Reports, 2021, 11, 5479.	3.3	18
81	Prostaglandin F2Î± agonists induced enhancement in collagen1 expression is involved in the pathogenesis of the deepening of upper eyelid sulcus. Scientific Reports, 2021, 11, 9002.	3.3	14
82	Omidenepag isopropyl ophthalmic solution for open-angle glaucoma and ocular hypertension: an update. Expert Review of Ophthalmology, 2021, 16, 243-250.	0.6	5
83	Adverse effects of prostaglandin analogues used in ophthalmological practice. Rossiiskii Oftal'mologicheskii Zhurnal, 2021, 14, 85-89.	0.4	3
84	ROCK inhibitors modulate the physical properties and adipogenesis of 3D spheroids of human orbital fibroblasts in different manners. FASEB BioAdvances, 2021, 3, 866-872.	2.4	7
85	Intraocular Pressure and Glaucoma in Thyroid Eye Disease. Ophthalmic Plastic and Reconstructive Surgery, 2022, 38, 219-225.	0.8	9
86	Addition of EP2 agonists to an FP agonist additively and synergistically modulates adipogenesis and the physical properties of 3D 3T3-L1 sphenoids. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 171, 102315.	2.2	6
87	Addition of ROCK inhibitors to prostaglandin derivative (PG) synergistically affects adipogenesis of the 3D spheroids of human orbital fibroblasts (HOFs). Human Cell, 2022, 35, 125-132.	2.7	4
88	Cross-Sectional Study of the Association between a Deepening of the Upper Eyelid Sulcus-Like Appearance and Wide-Open Eyes. PLoS ONE, 2014, 9, e96249.	2.5	13
90	Periocular changes in topical bimatoprost and latanoprost use. Turkish Journal of Medical Sciences, 2015, 45, 925-930.	0.9	5
91	Prostaglandin-associated periorbitopathy. Indian Journal of Ophthalmology, 2016, 64, 459.	1.1	8

#	Article	IF	Citations
92	Preserved to preservative free prostaglandin analogues in primary open angle glaucoma. International Journal of Basic and Clinical Pharmacology, 2013, 2, 696.	0.1	0
93	Drug-induced ocular side effects. , 2015, , 47-343.		0
94	Eye Medications and Its Effect on Orbital Fat and Cosmesis. , 2020, , 51-63.		0
95	Association of Deepening of the Upper Eyelid Sulcus with the Incidence of Blepharoptosis after Glaucoma Filtration Surgery. Seminars in Ophthalmology, 2020, 35, 348-351.	1.6	5
96	Bimatoprost in Dermatology. Indian Dermatology Online Journal, 2018, 9, 224-228.	0.5	2
97	Prostaglandin-associated periorbitopathy syndrome (PAPS): Addressing an unmet clinical need. Seminars in Ophthalmology, 2022, 37, 447-454.	1.6	7
98	Reactivities of a Prostanoid EP2 Agonist, Omidenepag, Are Useful for Distinguishing between 3D Spheroids of Human Orbital Fibroblasts without or with Gravesâ€™ Orbitopathy. Cells, 2021, 10, 3196.	4.1	2
99	Prostaglandin F2 and EP2 Agonists Exert Different Effects on 3D 3T3-L1 Spheroids during Their Culture Phase. Biomedicines, 2021, 9, 1821.	3.2	2
100	Dermatological adverse effects of antiâ€glaucoma eye drops: a review. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 661-670.	2.4	5
101	In Vivo Effects of Prostaglandin Analogues Application by Topical Drops or Retrobulbar Injections on the Orbital Fat of a Rat Model. Ocular Immunology and Inflammation, 2023, 31, 298-303.	1.8	2
103	Advances of the Side Effects of Prostaglandin Eye Drops. Hans Journal of Ophthalmology, 2022, 11, 55-69.	0.0	0
104	Shortening of interpupillary distance after topical prostaglandin analog eye drop application in an ophthalmic surgeon: A case report. American Journal of Ophthalmology Case Reports, 2022, 26, 101480.	0.7	0
105	Bimatoprost in dermatology. Indian Dermatology Online Journal, 2018, 9, 224.	0.5	14
106	Do Prostaglandin Analogue Lash Lengtheners Cause Eyelid Fat and Volume Loss?. Aesthetic Surgery Journal, 2022, 42, 1241-1249.	1.6	4
107	Commentary on: Do Prostaglandin Analogue Lash Lengtheners Cause Eyelid Fat and Volume Loss?. Aesthetic Surgery Journal, 0, , .	1.6	0
108	Bimatoprost. , 2022, , 155-160.		0
109	Prospects of the use of prostaglandin analogues in the treatment of patients with thyroid eye disease. Vestnik Oftalmologii, 2022, 138, 285.	0.5	0
110	Comparison of Soluble and Liposome Encapsulated, Sustained Release Latanoprost for Focal Adipose Reduction. Facial Plastic Surgery and Aesthetic Medicine, 2023, 25, 250-257.	0.9	1

#	Article	IF	Citations
111	Bimatoprost promotes satiety and attenuates body weight gain in rats fed standard or obesity-promoting diets.. Prostaglandins Leukotrienes and Essential Fatty Acids, 2022, 187, 102511.	2.2	1
112	Addition of ROCK Inhibitors Alleviates Prostaglandin-Induced Inhibition of Adipogenesis in 3T3L-1 Spheroids. Bioengineering, 2022, 9, 702.	3.5	2
113	Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment. TÃ¼rk Oftalmoloji Dergisi, 2023, 53, 8-12.	0.9	0
114	Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment. Ocular Surface, 2023, 29, 456-468.	4.4	6
115	Simultaneous Effects of a Selective EP2 Agonist, Omidenepag, and a Rho-Associated Coiled-Coil Containing Protein Kinase Inhibitor, Ripasudil, on Human Orbital Fibroblasts. Journal of Ocular Pharmacology and Therapeutics, 0, , .	1.4	0
116	How latanoprost changed glaucoma management. Acta Ophthalmologica, 2024, 102, .	1.1	1
117	Ocular Adnexal Changes After Antiglaucoma Medication Use. International Ophthalmology Clinics, 2023, 63, 47-58.	0.7	0
118	Side effects of drugs used in ocular treatment. Side Effects of Drugs Annual, 2023, , .	0.6	0
119	New role for the anandamide metabolite prostaglandin F2Î± ethanolamide: Rolling preadipocyte proliferation. Journal of Lipid Research, 2023, 64, 100444.	4.2	0
120	Recovery from Upper Eyelid Sulcus Deepening Following Switch from Prostaglandin Analogues to EP2 Receptor Agonist. Journal of Korean Ophthalmological Society, 2023, 64, 981-985.	0.2	0
121	Effect of retrobulbar prostaglandin analog injection on orbital fat in rats. International Ophthalmology, 0, , .	1.4	0
122	Challenging the "Topical Medications-Firstâ€•Approach to Glaucoma: A Treatment Paradigm in Evolution. Ophthalmology and Therapy, 2023, 12, 2823-2839.	2.3	1
123	Lower eyelid position before and after blepharoptosis repair. Orbit, 0, , 1-5.	0.8	0